Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by radical surgery for locally advanced oesophageal squamous cell carcinoma: meta-analysis.
Journal
BJS open
ISSN: 2474-9842
Titre abrégé: BJS Open
Pays: England
ID NLM: 101722685
Informations de publication
Date de publication:
02 11 2022
02 11 2022
Historique:
received:
20
05
2022
revised:
27
07
2022
accepted:
05
09
2022
entrez:
8
12
2022
pubmed:
9
12
2022
medline:
15
12
2022
Statut:
ppublish
Résumé
The literature lacks robust evidence comparing definitive chemoradiotherapy (dCRT) with neoadjuvant chemoradiotherapy and surgery (nCRS) for oesophageal squamous cell carcinoma (ESCC). This study aimed to compare long-term survival of these approaches in patients with ESCC. A systematic review performed according to PRISMA guidelines included studies identified from PubMed, Scopus, and Cochrane CENTRAL databases up to July 2021 comparing outcomes between dCRT and nCRS for ESCC. The main outcome measure was overall survival (OS), secondary outcome was disease-free survival (DFS). A meta-analysis was conducted using random-effects modelling to determine pooled adjusted multivariable hazard ratios (HRs). Ten studies including 14 092 patients were included, of which 30 per cent received nCRS. Three studies were randomized clinical trials (RCTs) and the remainder were retrospective cohort studies. dCRT and nCRS regimens were reported in six studies and surgical quality control was reported in two studies. Outcomes for OS and DFS were reported in eight and three studies respectively. Following meta-analysis, nCRS demonstrated significantly longer OS (HR 0.68, 95 per cent c.i. 0.54 to 0.87, P < 0.001) and DFS (HR 0.50, 95 per cent c.i. 0.36 to 0.70, P < 0.001) compared with dCRT. Neoadjuvant chemoradiotherapy followed by oesophagectomy correlated with improved survival compared with definitive chemoradiation in the treatment of ESCC; however, there is a lack of literature on RCTs.
Sections du résumé
BACKGROUND
The literature lacks robust evidence comparing definitive chemoradiotherapy (dCRT) with neoadjuvant chemoradiotherapy and surgery (nCRS) for oesophageal squamous cell carcinoma (ESCC). This study aimed to compare long-term survival of these approaches in patients with ESCC.
METHODS
A systematic review performed according to PRISMA guidelines included studies identified from PubMed, Scopus, and Cochrane CENTRAL databases up to July 2021 comparing outcomes between dCRT and nCRS for ESCC. The main outcome measure was overall survival (OS), secondary outcome was disease-free survival (DFS). A meta-analysis was conducted using random-effects modelling to determine pooled adjusted multivariable hazard ratios (HRs).
RESULTS
Ten studies including 14 092 patients were included, of which 30 per cent received nCRS. Three studies were randomized clinical trials (RCTs) and the remainder were retrospective cohort studies. dCRT and nCRS regimens were reported in six studies and surgical quality control was reported in two studies. Outcomes for OS and DFS were reported in eight and three studies respectively. Following meta-analysis, nCRS demonstrated significantly longer OS (HR 0.68, 95 per cent c.i. 0.54 to 0.87, P < 0.001) and DFS (HR 0.50, 95 per cent c.i. 0.36 to 0.70, P < 0.001) compared with dCRT.
CONCLUSION
Neoadjuvant chemoradiotherapy followed by oesophagectomy correlated with improved survival compared with definitive chemoradiation in the treatment of ESCC; however, there is a lack of literature on RCTs.
Identifiants
pubmed: 36477836
pii: 6880880
doi: 10.1093/bjsopen/zrac125
pmc: PMC9728519
pii:
doi:
Types de publication
Systematic Review
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.
Références
J Am Coll Surg. 2006 Apr;202(4):588-96; discussion 596-8
pubmed: 16571425
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Br J Surg. 2011 Aug;98(8):1124-31; discussion 1132
pubmed: 21674471
J Natl Compr Canc Netw. 2015 Feb;13(2):194-227
pubmed: 25691612
J Clin Oncol. 2014 Aug 10;32(23):2416-22
pubmed: 24982463
JAMA. 2011 Jun 8;305(22):2335-42
pubmed: 21642686
Lancet Oncol. 2011 Jul;12(7):681-92
pubmed: 21684205
J Gastrointest Surg. 2019 Apr;23(4):670-678
pubmed: 30788714
Ann Surg. 2007 Sep;246(3):363-72; discussion 372-4
pubmed: 17717440
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
J Clin Oncol. 2005 Apr 1;23(10):2310-7
pubmed: 15800321
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Ann Surg. 2015 Aug;262(2):286-94
pubmed: 25607756
Acta Oncol. 2003;42(3):207-17
pubmed: 12852697
Ann Surg. 2022 Mar 1;275(3):526-533
pubmed: 32865948
Ann Oncol. 2004 Jun;15(6):947-54
pubmed: 15151953
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
J Gastrointest Surg. 2017 Jan;21(1):126-136
pubmed: 27527093
World J Surg. 2018 May;42(5):1485-1495
pubmed: 29075858
J Clin Oncol. 2007 Apr 1;25(10):1160-8
pubmed: 17401004
Br J Surg. 2019 Feb;106(3):255-262
pubmed: 30395362
Br J Cancer. 2014 Jul 15;111(2):234-40
pubmed: 24921919
JCO Glob Oncol. 2020 Jun;6:828-836
pubmed: 32552112
N Engl J Med. 2002 Nov 21;347(21):1662-9
pubmed: 12444180
Syst Rev. 2018 Dec 21;7(1):242
pubmed: 30577874
Br J Surg. 2011 Jun;98(6):768-83
pubmed: 21462364
Anticancer Res. 2019 Sep;39(9):5123-5133
pubmed: 31519624
Lancet Oncol. 2005 Sep;6(9):659-68
pubmed: 16129366
Ann Surg. 2019 Dec;270(6):1005-1017
pubmed: 30817355
JMIR Res Protoc. 2015 Jun 29;4(2):e79
pubmed: 26121676
J Cancer. 2017 Feb 25;8(4):683-690
pubmed: 28367248
J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883
pubmed: 31319389
Ann Surg. 2022 Feb 1;275(2):e382-e391
pubmed: 33630459
J Thorac Cardiovasc Surg. 2018 Jun;155(6):2710-2721.e3
pubmed: 29548582
Front Oncol. 2021 Mar 10;11:628706
pubmed: 33777777
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Br J Surg. 2021 Jan 27;108(1):74-79
pubmed: 33640940
Ann Surg. 2019 Feb;269(2):291-298
pubmed: 29206677
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Ann Surg. 2015 Jul;262(1):79-85
pubmed: 24979602
J Clin Oncol. 2001 Jan 15;19(2):305-13
pubmed: 11208820